home All News open_in_new Full Article

Indegene Bets Big On Precision Pharma Marketing With $104 Million BioPharm Acquisition Says ICICI Securities

ICICI Securities maintains 'Add' rating on Indegene as it sees BioPharm acquisition to strengthen its presence in brand activation.


today 3 w. ago attach_file Economics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Technology
attach_file Politics
attach_file Economics
attach_file Politics


ID: 279266710
Add Watch Country

arrow_drop_down